Omnio specializes in plasminogen research, focusing on the development of recombinant plasminogen as a therapeutic solution for chronic wounds. Their innovative approach leverages the unique properties of plasminogen, which is recognized as a crucial regulatory molecule in the wound healing process. Unlike existing treatments, Omnio's recombinant plasminogen has demonstrated the ability to not only digest blood clots but also to promote new blood vessel formation, enhance cell migration and proliferation, and regulate the immune response, thereby reducing inflammation at the wound site. This multifaceted role positions plasminogen as a promising candidate for addressing the significant clinical and economic challenges posed by chronic wounds, particularly in diabetic patients who often experience impaired healing.

The company is committed to delivering transformative treatments where few effective pharmacological options currently exist. Their clinical development plan emphasizes the importance of addressing chronic wounds, which impose a substantial burden on healthcare systems globally. By focusing on diabetic patients, who are particularly vulnerable to chronic wounds, Omnio aims to provide a biologically active treatment that accelerates healing and improves patient quality of life. Their scalable and cost-effective production system for recombinant plasminogen ensures that this novel therapeutic can be made widely accessible, ultimately reducing the economic strain on healthcare resources while enhancing patient outcomes.

Sweden

Omnio AB is a biopharmaceutical company dedicated to revolutionizing the treatment of diabetic foot ulcers (DFUs) through the development of recombinant plasminogen therapeutics. 

Omnio

Company Details